Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
Angelo Di Leo(Nuovo Ospedale di Prato), Stephen Johnston(Royal Marsden Hospital), Keun Seok Lee(National Cancer Center), Eva Ciruelos(Hospital Universitario 12 De Octubre), Per Eystein Lønning(Haukeland University Hospital), Wolfgang Janni(University Hospital Ulm), Ruth O’Regan(University of Wisconsin–Madison), Marie‐Ange Mouret‐Reynier(Centre Jean Perrin), Dimitar Kalev(Medical University of Varna), Daniel Egle, Tibor Csőszi, Roberto Bordonaro(Ospedale Garibaldi), Thomas Decker(Ravensburg University of Cooperative Education), Vivianne C. G. Tjan‐Heijnen(Maastricht University), Sibel Blau(Northwest Medical Specialties), Alessio Schirone(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Denis Weber(Novartis (Switzerland)), Mona El-Hashimy(Novartis (United States)), Bharani Dharan(Novartis (United States)), Dalila Sellami(Novartis (United States)), Thomas Bachelot(Centre Léon Bérard)
Cited by 381
Abstract
Related Papers
No related papers found
Powered by citation graph analysis